Browsing Tag
Oncology
318 posts
Hanmi Pharmaceutical to acquire Aptose Biosciences in C$2.41-per-share deal with 28% premium
Find out how Hanmi Pharmaceutical’s acquisition of Aptose Biosciences is reshaping the AML treatment landscape today!
Johnson & Johnson grabs RIPTAC cancer tech in $3bn Halda Therapeutics deal
Johnson & Johnson acquires Halda Therapeutics for $3.05B, expanding its oncology portfolio with precision prostate cancer treatments. Find out what’s next.
Major oncology milestone as Organon and Henlius secure FDA approval for POHERDY, the first U.S. biosimilar to PERJETA
Find out how FDA approval of POHERDY, the first U.S. biosimilar to PERJETA, may transform HER2-positive breast cancer treatment costs and patient access.
Is Aptamer Group (LON: APTA) finally seeing sustained pharma traction with its Optimer platform?
Aptamer Group grows FY26 contracts to £1.95M with pharma repeat wins. Find out how its IP-heavy Optimer platform is gaining commercial traction.
Radiopharm Theranostics begins third-cohort enrolment in Phase 1 177Lu-RAD204 trial targeting PD-L1 tumours
Find out how Radiopharm Theranostics is advancing 177Lu-RAD204 in PD-L1-positive tumours as it begins third-cohort enrolment in its Phase 1 trial.
Is Oracle building the next operating system for oncology? Inside its AI push with Ci4CC
Oracle and Ci4CC join forces to drive AI and data science innovation in oncology. Find out how this partnership could reshape cancer care infrastructure.
Darzalex Faspro moves closer to FDA approval as first therapy for high-risk smoldering multiple myeloma
Find out how Darzalex Faspro could become the first FDA-approved therapy for high-risk smoldering multiple myeloma, reshaping early myeloma care.
FDA approves GSK’s Blenrep for myeloma—what sets it apart from CAR-T options?
GSK’s Blenrep approved by the FDA for relapsed multiple myeloma after Phase III trial success. Learn what this means for U.S. patients and global expansion.
Guardant Health (NASDAQ: GH) surges 27% after blowout quarter: What it means for diagnostics investors
Find out how Guardant Health’s strong Q3 performance triggered a diagnostics rally — and what it means for investors in the early-detection boom.
N2OFF enters cancer-drug discovery market through MitoCareX merger
Find out how N2OFF’s merger with MitoCareX is reshaping its business and targeting pancreatic & lung cancers!